The dose of Haldol Decanoate 50 or Haldol Decanoate 100 should be expressed in terms of its haloperidol content. The starting dose of haloperidol decanoate should be based on the patient's age, clinical history, physical condition, and response to previous antipsychotic therapy. The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed. For patients previously maintained on low doses of antipsychotics (. up to the equivalent of 10 mg/day oral haloperidol), it is recommended that the initial dose of haloperidol decanoate be 10–15 times the previous daily dose in oral haloperidol equivalents; limited clinical experience suggests that lower initial doses may be adequate.
If you are eligible, you may be able to lower your out-of-pocket costs for STELARA®, including deductible, co-pay, and coinsurance medication costs. With Janssen CarePath Savings Program for STELARA®, eligible patients pay just $5 per dose for their STELARA® medication costs, with a $20,000 maximum program benefit each calendar year. Patients using Medicare, Medicaid or any other federally-funded programs to pay for STELARA® are not eligible to participate in the program. Before the calendar year ends, you will receive information and eligibility requirements for continued participation in the program. There is no income requirement.
Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL CONSTA® and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.